SCHEDULE: Vanguard Discloses 5.24% Stake in 10X Genomics

Vanguard Capital Management reports beneficial ownership of 6,166,597 shares, representing 5.24% of 10X Genomics Inc.'s common stock, as of March 31, 2026.

Summary

• Vanguard Capital Management, along with its affiliates, has filed a Schedule 13G indicating beneficial ownership of 6,166,597 shares of 10X Genomics Inc. common stock.
• This holding represents 5.24% of the total class of securities.
• The filing specifies sole voting power for 897,011 shares and sole dispositive power for 6,166,597 shares.
• The reporting entity is identified as an investment adviser, and the securities were acquired and are held in the ordinary course of business.
• The filing date is April 29, 2026, reflecting the ownership as of March 31, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing, as it indicates substantial investment and confidence from a major institutional investor like Vanguard, suggesting a belief in the company's future value.

Positives

• Vanguard's significant stake suggests confidence in 10X Genomics' long-term prospects.
• The filing indicates that Vanguard funds and managed accounts have the right to receive dividends and proceeds from the sale of these securities, implying potential income generation for these entities.

Negatives

• The filing does not contain any negative financial or operational information about 10X Genomics itself, as it is a disclosure of ownership by a third party.

Risks

• The filing does not explicitly mention any risks related to 10X Genomics' business operations or financial performance.

Future Outlook

The filing does not contain forward-looking statements or guidance from 10X Genomics. It is a disclosure of beneficial ownership by Vanguard.

Management Comments

• "In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Capital Management LLC and the following affiliates of Vanguard Capital Management LLC or business divisions of such affiliates: Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC and Vanguard Investments Australia Ltd."
• "This Schedule 13G includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Capital Management LLC exercises dispositive power, in addition to securities held by clients over which the affiliates or business divisions of such affiliates indicated above exercise dispositive and/or voting power."
• "This Schedule 13G does not include securities, if any, beneficially owned by other subsidiaries or affiliates of Vanguard Capital Management LLC, or business divisions of such subsidiaries, whose ownership of securities is disaggregated from that of the reporting business unit in accordance with such release."
• "Vanguard Capital Management, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that a Schedule 13G filing by a major institutional investor like Vanguard, indicating a significant ownership stake (over 5%), often signals a positive view on the company's growth potential within the biotechnology and life sciences tools sector. Such filings can attract further investor attention.

Stakeholder Impact

• Shareholders: The filing may increase investor confidence and potentially influence share price due to Vanguard's significant stake.
• Vanguard Funds and Clients: These entities benefit from the potential for dividends and capital appreciation on their investment in 10X Genomics.

Next Steps

• Vanguard will continue to hold or manage its position in 10X Genomics Inc. common stock.
• 10X Genomics Inc. will continue its business operations and regulatory reporting.

Key Dates

Recommendation

This filing is a disclosure of beneficial ownership by Vanguard and does not contain operational or financial results of 10X Genomics. While Vanguard's investment is a positive signal, it does not provide sufficient information for a buy or sell recommendation on its own. A 'hold' recommendation is appropriate pending further analysis of the company's performance.

Keywords

10X Genomics, Vanguard Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, SEC Filing, Vanguard Funds